Bausch Health Companies Inc. (NYSE:BHC) Expected to Post Earnings of $1.03 Per Share

Equities analysts forecast that Bausch Health Companies Inc. (NYSE:BHCGet Rating) will announce earnings of $1.03 per share for the current fiscal quarter, according to Zacks. Three analysts have provided estimates for Bausch Health Companies’ earnings. The highest EPS estimate is $1.08 and the lowest is $0.99. Bausch Health Companies posted earnings of $1.04 per share in the same quarter last year, which would indicate a negative year over year growth rate of 1%. The business is scheduled to report its next quarterly earnings results before the market opens on Monday, January 1st.

According to Zacks, analysts expect that Bausch Health Companies will report full year earnings of $4.50 per share for the current year, with EPS estimates ranging from $4.34 to $4.87. For the next year, analysts expect that the business will report earnings of $4.92 per share, with EPS estimates ranging from $4.31 to $5.20. Zacks Investment Research’s EPS calculations are a mean average based on a survey of analysts that that provide coverage for Bausch Health Companies.

Bausch Health Companies (NYSE:BHCGet Rating) last released its earnings results on Wednesday, February 23rd. The company reported $1.27 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.08 by $0.19. The firm had revenue of $2.20 billion during the quarter, compared to analysts’ expectations of $2.21 billion. Bausch Health Companies had a negative net margin of 11.24% and a negative return on equity of 708.85%. Bausch Health Companies’s revenue for the quarter was down .8% on a year-over-year basis. During the same period in the previous year, the company earned $1.33 EPS.

Several brokerages have recently issued reports on BHC. StockNews.com raised shares of Bausch Health Companies from a “hold” rating to a “buy” rating in a research note on Tuesday, March 29th. Zacks Investment Research raised shares of Bausch Health Companies from a “hold” rating to a “buy” rating and set a $29.00 price objective for the company in a research note on Tuesday, January 4th. Royal Bank of Canada lowered their price objective on shares of Bausch Health Companies from $40.00 to $34.00 and set an “outperform” rating for the company in a research note on Tuesday, February 1st. Finally, TheStreet lowered shares of Bausch Health Companies from a “c-” rating to a “d+” rating in a report on Monday, March 28th. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Buy” and an average target price of $31.33.

Shares of NYSE BHC traded down $0.73 during trading on Friday, hitting $19.01. 6,243,752 shares of the company traded hands, compared to its average volume of 3,297,313. Bausch Health Companies has a 1 year low of $18.20 and a 1 year high of $33.00. The company has a 50-day moving average price of $22.69 and a 200-day moving average price of $24.98. The firm has a market capitalization of $6.86 billion, a P/E ratio of -7.15, a P/E/G ratio of 0.39 and a beta of 1.60.

In other Bausch Health Companies news, insider Robert Spurr sold 1,595 shares of the business’s stock in a transaction on Thursday, April 14th. The shares were sold at an average price of $22.19, for a total value of $35,393.05. Following the transaction, the insider now owns 90,506 shares in the company, valued at approximately $2,008,328.14. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Joseph F. Gordon sold 6,338 shares of the business’s stock in a transaction on Tuesday, March 1st. The stock was sold at an average price of $23.82, for a total transaction of $150,971.16. The disclosure for this sale can be found here. Insiders have sold a total of 16,668 shares of company stock worth $378,570 in the last 90 days. Company insiders own 13.75% of the company’s stock.

A number of hedge funds have recently modified their holdings of the business. Creative Financial Designs Inc. ADV raised its stake in shares of Bausch Health Companies by 525.0% in the 1st quarter. Creative Financial Designs Inc. ADV now owns 1,250 shares of the company’s stock valued at $29,000 after purchasing an additional 1,050 shares in the last quarter. Amplius Wealth Advisors LLC acquired a new stake in shares of Bausch Health Companies in the 4th quarter valued at about $30,000. Glassman Wealth Services raised its stake in shares of Bausch Health Companies by 71.4% in the 4th quarter. Glassman Wealth Services now owns 1,152 shares of the company’s stock valued at $32,000 after purchasing an additional 480 shares in the last quarter. Sterling Investment Advisors Ltd. acquired a new stake in shares of Bausch Health Companies in the 3rd quarter valued at about $56,000. Finally, Sargent Bickham Lagudis LLC acquired a new stake in shares of Bausch Health Companies in the 1st quarter valued at about $57,000. Hedge funds and other institutional investors own 71.26% of the company’s stock.

Bausch Health Companies Company Profile (Get Rating)

Bausch Health Companies Inc, together with its subsidiaries, develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through five segments: Bausch + Lomb, Salix, International Rx, Ortho Dermatologics, and Diversified Products.

Recommended Stories

Get a free copy of the Zacks research report on Bausch Health Companies (BHC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Bausch Health Companies (NYSE:BHC)

Receive News & Ratings for Bausch Health Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bausch Health Companies and related companies with MarketBeat.com's FREE daily email newsletter.